Mode
Text Size
Log in / Sign up
N/A Completed N=10 Treatment

Bariatric Embolization of Arteries With Imaging Visible Embolics (BEATLES)

Source: ClinicalTrials.gov NCT04197336 ↗
Enrolled (actual)
10
Serious AEs
30.0%
Results posted
Mar 2025
Primary outcomePrimary: Change in Body Weight as Assessed by BMI (kg/m^2) — 43.7 kg/m^2

Summary

The BEATLES study is an investigator-initiated, prospective, double-blinded, randomized, sham-controlled study that will assess the impact of bariatric embolization on the systemic levels of obesity-related hormones and, as a consequence, on weight loss. The goal of this study is to help treat obesity combining a lifestyle program and a minimally invasive, angiographic (i.e., through blood vessels) approach.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Body Weight as Assessed by BMI (kg/m^2)
43.7
PRIMARY
Change in Body Weight (Pounds)
14.3

Eligibility Criteria

Inclusion Criteria

  • Male or female, aged ≥21 and ≤70 years
  • Willing, able, and mentally competent to provide written informed consent
  • Obese patients with a BMI ≥35 kg/m2
  • Weight ≤400 lb
  • Vascular anatomy (including celiac, hepatic, and gastric arteries) that in the opinion of the interventional radiologist is amendable to bariatric embolization, as assessed via 3D CT angiography
  • Suitable for protocol therapy, as determined by the interventional radiology investigator
  • Adequate hematologic (neutrophils>1.5x109/L, platelets>70x109/L, international normalized ratio (INR 60milliliter mL/min. 1.73m2) function
  • For females of reproductive potential: agreement to use of highly effective contraception
  • for duration of study participation
  • Patients who have failed conservative weight loss therapies such as supervised low calorie diets combined with behavior therapy and exercise
  • Live or work within 65 miles of the enrolling institution in case a catastrophic post embolization event occurs

Exclusion Criteria

  • hemoglobin A1c greater than 8%
  • Patients who are currently taking either Insulin or sulfonylurea (medication changes are allowed)
  • Prior history of gastric, pancreatic, hepatic, and/or splenic surgery
  • Prior radiation therapy to the upper abdomen
  • Prior embolization to the stomach, spleen, or liver
  • Cirrhosis
  • Known portal venous hypertension
  • Active peptic ulcer disease
  • Significant risk factors for peptic ulcer disease, including daily NSAID use
  • Large hiatal hernia, defined as >5 cm in size
  • Active H. Pylori infection
  • Known aortic pathology, such as aneurysm or dissection
  • Renal insufficiency, as evidenced by an estimated glomerular filtration rate of <60 milliliter(mL)/min
  • Major comorbidity, such as active cancer, significant cardiovascular disease, or peripheral arterial disease
  • Pregnancy
  • Pre-existing chronic abdominal pain
  • Positive stool occult blood study
  • GI bleeding or bleeding diathesis within 5 years
  • Weight loss (intentional or unintentional) of more than or equal to 5% of body weight in the 6 months prior to randomization
  • A weight loss greater than 6lb during the weight management run- in
  • Use of anti-obesity medications in the 12 months prior to screening
  • Endoscopic findings that would preclude bariatric embolization (at the discretion of the study team)
  • History of gastric motility disorders or an abnormal nuclear gastric motility examination (to be performed in diabetic subjects only)
  • American Society of Anesthesiologists Class 4 or 5 (very high risk surgical candidates: class 4=incapacitating disease that is a constant threat to life) at the time of screening for enrollment into the study - this exclusion criterion exists, because of the possibility that surgical intervention will be needed if the study intervention subsequently leads to severe adverse effects
  • Inflammatory bowel disease
  • Autoimmune disease or HIV+
  • History of allergy to iodinated contrast media
  • Failure to comply with pre-procedure weight management "run-in", or other pre-procedural visits (specifically, participants must complete 80% of weight management and Lose It! Food tracking, and 100% of one-time visits, i.e. MRI, computed tomography angiography (CTA), endoscopy)
  • Applicability of any contraindication regarding patient's vasculature as per Instruction for Use
  • Inability to have an MRI scan (i.e., metal implants or claustrophobia)
  • Smokers/vape users/tobacco use
  • Active or new-onset endocrine disorders (stable disease acceptable)
  • Other unforeseen conditions that may make patients unsuitable for the procedure (study team discretion)

Exclusion Criteria (Psychiatric):

  • As determined by clinical judgment based on Clinical Interview, psychological/behavioral measures, medical records, previous mental health records/other collateral information (as available) and consistent with diagnostic and statistical manual of mental disorders (DSM) -5 criteria:
  • Diagnosis of severe mental illnes
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04197336). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search